title: Real-world use of ticagrelor and prasugrel in patients with NSTEMI undergoing percutaneous coronary intervention.
authors.affiliation: aDivision of Cardiology bDivision of Hematology, Biomedical Department of Internal Medicine and Specialties (DiBiMIS), Paolo Giaccone Hospital, University of Palermo, Palermo, Italy.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Sucato
authors.forename: Egle
authors.initials: E
authors.lastname: Corrado
authors.forename: Carmelo
authors.initials: C
authors.lastname: Castellana
authors.forename: Michele
authors.initials: M
authors.lastname: Carella
authors.forename: Simona
authors.initials: S
authors.lastname: Raso
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Coppola
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Andolina
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Novo
authors.forename: Salvatore
authors.initials: S
authors.lastname: Evola
authors.forename: Salvatore
authors.initials: S
authors.lastname: Novo
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000072658:Non-ST Elevated Myocardial Infarction / Q000628:therapy*; D062645:Percutaneous Coronary Intervention; D000068799:Prasugrel Hydrochloride / Q000627:therapeutic use*; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077486:Ticagrelor; D016896:Treatment Outcome
chemical_list: D058921:Purinergic P2Y Receptor Antagonists; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine